Serum Protein Electrophoresis in Plasma Cell Disorders

Introduction to SPEP

• The National Comprehensive Cancer Network recommends Serum Protein Electrophoresis (SPEP) as a critical diagnostic test to detect and evaluate monoclonal proteins (M-proteins) in the blood, primarily used to diagnose and monitor plasma cell disorders such as multiple myeloma and related conditions 1, 2

Diagnostic Utility of SPEP

• SPEP specifically identifies the presence, type, and quantity of M-proteins (monoclonal proteins), which are abnormal antibodies produced by clonal proliferation of plasma cells, as recommended by the National Comprehensive Cancer Network 2, 3
• The National Comprehensive Cancer Network suggests that SPEP is a fundamental component of the diagnostic workup for suspected plasma cell disorders, with results guiding further testing and management 1, 2

Interpretation and Clinical Significance

• Abnormal findings on SPEP include a monoclonal spike (M-spike), which indicates potential multiple myeloma, Waldenström's macroglobulinemia, or monoclonal gammopathy of undetermined significance (MGUS), according to the National Comprehensive Cancer Network 2

Additional Testing and Clinical Applications

• The National Comprehensive Cancer Network recommends that when SPEP shows an abnormal pattern, follow-up testing should include serum immunofixation electrophoresis (SIFE), quantitative immunoglobulin levels (IgG, IgA, IgM), serum free light chain (FLC) assay, and 24-hour urine collection for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE) 1, 2, 4
• SPEP is used for initial screening for plasma cell disorders, quantifying M-protein levels to track disease progression, monitoring response to treatment, and detecting disease recurrence, as suggested by the National Comprehensive Cancer Network 1, 2, 5

Referral to a Specialist

• The National Comprehensive Cancer Network recommends that any detected monoclonal protein on SPEP should prompt referral to a hematologist/oncologist, with urgent referral (within 1-2 weeks) recommended for patients with significant M-protein spike, accompanying symptoms, anemia, renal dysfunction, or hypercalcemia 4

M Band Detection and Interpretation in Multiple Myeloma

Introduction to M Band

• The M band is a visual marker of a monoclonal protein (M-protein) - a single type of abnormal antibody made by a clone of cancerous plasma cells, typically appearing in the gamma region of serum protein electrophoresis (SPEP) 6, 7

Clinical Significance of M Band

• Detection of an M band on SPEP is a fundamental step in diagnosing multiple myeloma and must be followed by immunofixation to characterize which specific antibody type (IgG, IgA, IgM) and light chain (kappa or lambda) is being produced 6, 7
• The height and area under the M-spike can be measured to quantify how much abnormal protein is present, with MGUS (a benign precursor condition) typically having an M-protein less than 30 g/L, while in multiple myeloma it is typically higher 6, 8, 9

Diagnostic Considerations

• Approximately 15-20% of myeloma cases produce only light chains (not complete antibodies), which may not create a visible spike on standard SPEP and require urine testing or serum free light chain assays for detection 10
• Some cases are truly "non-secretory" and produce no detectable M-protein at all 10

Follow-up Testing

• Essential follow-up testing includes immunofixation electrophoresis to identify the exact type of M-protein, quantitative immunoglobulin levels (IgG, IgA, IgM) 10
• Serum free light chain assay with kappa/lambda ratio, 24-hour urine collection for urine protein electrophoresis, bone marrow biopsy to assess plasma cell percentage, complete blood count, calcium, creatinine to check for organ damage, and skeletal survey to look for bone lesions 10

Laboratory Tests for Plasma Cell Disorders

Diagnostic Tests

• The National Comprehensive Cancer Network recommends quantifying M-protein levels using SPEP and UPEP to establish baseline disease burden in patients with suspected multiple myeloma, Waldenström's macroglobulinemia, monoclonal gammopathy of undetermined significance (MGUS), and related conditions 11
• The National Comprehensive Cancer Network suggests monitoring treatment response by tracking changes in M-protein concentration over time using SPEP and UPEP 11
• The National Comprehensive Cancer Network recommends detecting disease recurrence during surveillance using SPEP and UPEP 11
• Serum immunofixation electrophoresis (SIFE) is recommended to identify the exact immunoglobulin type (IgG, IgA, IgM) and light chain (kappa or lambda) after an M-spike is detected on SPEP 11
• Serum free light chain (FLC) assay with kappa/lambda ratio is recommended to assess plasma cell disorders, especially in patients with lytic bone lesions or suspected myeloma 11
• The combination of SPEP plus serum free light chain analysis achieves 100% sensitivity for detecting plasma cell disorders, and can eliminate the need for 24-hour urine collection in initial screening 11

Special Considerations

• Approximately 3% of patients have truly non-secretory myeloma with no detectable M-protein on either SPEP or UPEP, highlighting the importance of additional diagnostic tests 11

Serum Protein Electrophoresis in Diagnosing Plasma Cell Disorders

Primary Clinical Applications

• Monoclonal gammopathies are significantly more common in patients with polyneuropathy (10% prevalence) compared to the general population, making SPEP a high-yield screening test in this context, particularly for diagnosing multiple myeloma, Waldenström's macroglobulinemia, and monoclonal gammopathy of undetermined significance (MGUS) 12
• SPEP is one of the three highest-yield screening tests for distal symmetric polyneuropathy (DSP), alongside blood glucose and serum B12 with metabolites, and is useful for evaluating polyneuropathy 12
• Serum protein immunofixation electrophoresis (IFE) is more sensitive than SPEP, especially for detecting small or non-malignant monoclonal gammopathies, with IFE identifying 17% of monoclonal gammopathies that SPEP missed 12

Important Limitations and Pitfalls

• Serum immunofixation electrophoresis is more sensitive than SPEP and should be used when clinical suspicion is high despite negative SPEP, highlighting the importance of additional diagnostic tests 12

Interpretation of Serum Protein Electrophoresis Changes in Multiple Myeloma

Clinical Significance and Monitoring

• The American Society of Clinical Oncology (ASCO) and Canadian Cancer Organization (CCO) guidelines recommend following all measurable parameters, including serum protein electrophoresis, to assess treatment response in multiple myeloma patients 13
• The National Comprehensive Cancer Network (NCCN) recommends serum protein electrophoresis (SPEP) as a fundamental tool for quantifying M-protein levels to track disease progression and monitor treatment response in multiple myeloma patients 14
• Changes in M-protein concentration over time using SPEP are the primary method for determining treatment efficacy in multiple myeloma patients 13
• A partial response (PR) or very good partial response (VGPR) to therapy is consistent with a significant reduction in M-protein burden, as indicated by improvements in SPEP results 13
• However, SPEP alone cannot definitively categorize the depth of response according to International Myeloma Working Group (IMWG) criteria 13

Essential Next Steps for Complete Assessment

• To properly classify the response depth and confirm favorable findings, additional tests such as serum immunofixation electrophoresis (SIFE), quantitative immunoglobulin levels, serum free light chain (FLC) assay, and 24-hour urine protein electrophoresis are mandatory 13, 14
• Serum immunofixation electrophoresis (SIFE) is necessary to determine if the M-protein is still detectable and to confirm its type 13, 14
• Quantitative immunoglobulin levels (IgG, IgA, IgM) are required to assess the specific monoclonal immunoglobulin and check for immune paresis 13, 14
• Serum free light chain (FLC) assay with kappa/lambda ratio is essential for sensitive monitoring, especially important as disease can evolve to light chain escape 13, 14

Critical Monitoring Considerations

• Response assessment should be performed after each cycle initially, then every other cycle once a response trend is observed, and less frequently once in plateau phase 13
• Approximately 15-20% of myeloma cases can develop "light chain escape" where disease evolves to produce only light chains, which may not be adequately captured by standard SPEP 13
• Serum free light chain levels should be followed in addition to SPEP to detect this phenomenon 13
• Some patients (1-3%) have non-secretory myeloma with no detectable M-protein, requiring alternative monitoring methods 15

Serum Protein Electrophoresis in Plasma Cell Disorders

Diagnostic Testing

• The National Comprehensive Cancer Network recommends ordering serum protein electrophoresis (SPEP) with concurrent serum immunofixation electrophoresis (SIFE) and serum free light chain (FLC) assay to achieve adequate diagnostic sensitivity in patients with suspected plasma cell disorders 16
• Approximately 20% of patients have secretory urinary M-proteins that may not be adequately captured by serum testing alone, highlighting the importance of concurrent urine testing 16
• The combination of SPEP plus FLC analysis achieves 100% sensitivity for detecting plasma cell disorders, particularly light chain-only disease 16

Limitations of SPEP

• SPEP has only 71% sensitivity for detecting plasma cell disorders when lytic bone lesions are present, emphasizing the need for comprehensive diagnostic testing 16
• Approximately 3% of patients have truly non-secretory myeloma with no detectable M-protein on either SPEP or UPEP, requiring bone marrow biopsy and imaging for diagnosis 16

Additional Baseline Studies

• The National Comprehensive Cancer Network recommends obtaining a complete blood count (CBC) with differential, comprehensive metabolic panel, beta-2 microglobulin, and LDH for prognostic stratification, as well as a skeletal survey or whole-body low-dose CT to evaluate for lytic bone lesions 16